Daniel Sullivan, MD

Where You Are:
Daniel Sullivan, MD

Senior Member

Office  (888) 663-3488

Education And Training
  • Fellow, University of Florida, 1988 - Hematology/Oncology
  • Resident, University of Florida, 1985 - Internal Medicine
  • MD, University of Louisville, 1981


Research in our laboratory has focused on defining the mechanisms of drug resistance to inhibitors of mammalian DNA topoisomerase I, II alpha, and II beta. These enzymes are the targets of several commonly used anti-tumor agents, including etoposide, doxorubicin, mitoxantrone, topotecan and irinotecan. Recently, we have found that the trafficking of topoisomerase I and/or II to the cytoplasm is a mechanism of cellular drug resistance that can occur in the absence of drug exposure. Defining the nuclear export signal of topoisomerase II alpha is a current project in the laboratory. Our lab is also involved in several translational research studies, which aim to define the role of quantitative and qualitative alterations in topoisomerases in determining cellular sensitivity to topoisomerase inhibitors in vivo.. Thus, tumor biopsies from patients with multiple myeloma, AML, non-Hodgkin's lymphoma, small cell lung cancer, rectal carcinoma, and malignant melanoma are currently being examined for this purpose.

  • Yap TA, Yan L, Patnaik A, Tunariu N, Biondo A, Fearen I, Papadopoulos K, Olmos D, Baird RD, Delgado LM, Tetteh E, Beckman RA, Lupinacci L, Riisnaes R, Decordova S, Heaton SP, Swales K, deSouza NM, Leach MO, Garrett MD, Sullivan DM, de Bono JS, Tolcher A. Interrogating Two Schedules of the AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors Incorporating Novel Pharmacodynamic and Functional Imaging Biomarkers. Clin Cancer Res. 2014 Nov;20(22):5672-5685. Pubmedid: 25239610.
  • Brana I, Berger R, Golan T, Haluska P, Edenfield J, Fiorica J, Stephenson J, Martin LP, Westin S, Hanjani P, Jones MB, Almhanna K, Wenham RM, Sullivan DM, Dalton WS, Gunchenko A, Cheng JD, Siu LL, Gray JE. A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours. Brit J Cancer. 2014 Nov;111(10):1932-1944. Pubmedid: 25290091.
  • Soliman HH, Jackson E, Neuger T, Dees EC, Harvey RD, Han H, Ismail-Khan R, Minton S, Vahanian NN, Link C, Sullivan DM, Antonia S. A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors. Oncotarget. 2014 Sep;5(18):8136-8146. Pubmedid: 25327557.
  • Molife LR, Yan L, Vitfell-Rasmussen J, Zernhelt AM, Sullivan DM, Cassier PA, Chen E, Biondo A, Tetteh E, Siu LL, Patnaik A, Papadopoulos KP, de Bono JS, Tolcher AW, Minton S. Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors. J Hematol Oncol. 2014 Sep;7(1):1. Pubmedid: 24387695. Pmcid: PMC3884022.
  • Turner JG, Dawson J, Cubitt CL, Baz R, Sullivan DM. Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents. Semin Cancer Biol. 2014 Aug;27C:62-73. Pubmedid: 24631834. Pmcid: PMC4108511.
  • Baz RC, Shain KH, Hussein MA, Lee JH, Sullivan DM, Finleyoliver E, Nardelli LA, Nodzon LA, Zhao X, Ochoa-Bayona JL, Nishihori T, Dalton WS, Alsina M. Phase II study of pegylated liposomal doxorubicin, low-dose dexamethasone, and lenalidomide in patients with newly diagnosed multiple myeloma. Am J Hematol. 2014 Jan;89(1):62-67. Pubmedid: 24030918.
  • Hudis C, Swanton C, Janjigian YY, Lee R, Sutherland S, Lehman R, Chandarlapaty S, Hamilton N, Gajria D, Knowles J, Shah J, Shannon K, Tetteh E, Sullivan DM, Moreno C, Yan L, Han HS. A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors. Breast Cancer Res. 2013 Nov;15(6):R110. Pubmedid: 24252402.
  • Cubitt CL, Menth J, Dawson J, Martinez GV, Foroutan P, Morse DL, Bui MM, Letson GD, Sullivan DM, Reed DR. Rapid screening of novel agents for combination therapy in sarcomas. Sarcoma. 2013 Nov;2013:365723. Pubmedid: 24282374. Pmcid: PMC3824404.
  • Almhanna K, Cubitt CL, Zhang S, Kazim S, Husain K, Sullivan D, Sebti S, Malafa M. MK-2206, an Akt inhibitor, enhances carboplatinum/paclitaxel efficacy in gastric cancer cell lines. Cancer Biol Ther. 2013 Oct;14(10):932-936. Pubmedid: 23917345. Pmcid: PMC3926890.
  • Baz R, Miladinovic B, Patel A, Ho VQ, Shain KH, Alsina M, Nishihori T, Ochoa-Bayona JL, Sullivan DM, Dalton WS, Djulbegovic B. Sequence of novel agents in multiple myeloma: an instrumental variable analysis. Leuk Res. 2013 Sep;37(9):1077-1082. Pubmedid: 23809054.
  • Abrams JS, Mooney MM, Zwiebel JA, Korn EL, Friedman SH, Finnigan SR, Schettino PR, Denicoff AM, Kruhm MG, Montello M, Misra RR, Ansher SS, Dipiazza KJ, Souhan EM, Wickerham DL, Giantonio BJ, O'Donnell RT, Sullivan DM, Soto NI, Fleming GF, Prindiville SA, Petryshyn RA, Hautala JA, Grad O, Zuckerman BL, Meyer RM, Yao JC, Baker LA, Buckner JC, Hortobagyi GN, Doroshow JH. Implementation of timeline reforms speeds initiation of National Cancer Institute-sponsored trials. J Natl Cancer Inst. 2013 Jul;105(13):954-959. Pubmedid: 23776198. Pmcid: PMC3699438.
  • Nishihori T, Ochoa-Bayona JL, Kim J, Pidala J, Shain K, Baz R, Sullivan D, Jim HS, Anasetti C, Alsina M. Allogeneic hematopoietic cell transplantation for consolidation of VGPR or CR for newly diagnosed multiple myeloma. Bone Marrow Transplant. 2013 Apr;48(9):1179-1184. Pubmedid: 23542223.
  • Richardson PG, Siegel D, Baz R, Kelley SL, Munshi NC, Laubach J, Sullivan D, Alsina M, Schlossman R, Ghobrial IM, Doss D, Loughney N, McBride L, Bilotti E, Anand P, Nardelli L, Wear S, Larkins G, Chen M, Zaki MH, Jacques C, Anderson KC. Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Blood. 2013 Mar;121(11):1961-1967. Pubmedid: 23243282. Pmcid: PMC4123324.
  • Turner JG, Dawson J, Emmons MF, Cubitt CL, Kauffman M, Shacham S, Hazlehurst LA, Sullivan DM. CRM1 Inhibition Sensitizes Drug Resistant Human Myeloma Cells to Topoisomerase II and Proteasome Inhibitors both In Vitro and Ex Vivo. J Cancer. 2013;4(8):614-625. Pubmedid: 24155773. Pmcid: PMC3805989.
  • Ramakrishnan R, Huang C, Cho HI, Lloyd M, Johnson J, Ren X, Altiok S, Sullivan D, Weber J, Celis E, Gabrilovich DI. Autophagy induced by conventional chemotherapy mediates tumor cell sensitivity to immunotherapy. Cancer Res. 2012 Nov;72(21):5483-5493. Pubmedid: 22942258.
  • Lush RM, Patnaik A, Sullivan D, Papadopoulos KP, Trucksis M, McCrea J, Cerchio K, Li X, Stroh M, Selverian D, Orford K, Ebbinghaus S, Agrawal N, Iwamoto M, Wagner JA, Tolcher A. A single supratherapeutic dose of ridaforolimus does not prolong the QTc interval in patients with advanced cancer. Cancer Chemother Pharmacol. 2012 Oct;70(4):567-574. Pubmedid: 22878520. Pmcid: PMC3456920.
  • Perkins JB, Kim J, Anasetti C, Fernandez HF, Perez LE, Ayala E, Kharfan-Dabaja MA, Tomblyn MR, Sullivan DM, Pidala JA, Field TL. Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation. Biol Blood Marrow Tran. 2012 Jul;18(7):1099-1107. Pubmedid: 22198540.
  • Jacobsen PB, Wells KJ, Meade CD, Quinn GP, Lee JH, Fulp WJ, Gray JE, Baz RC, Springett GM, Levine RM, Markham MJ, Schreiber FJ, Cartwright TH, Burke JM, Siegel RD, Malafa MP, Sullivan D. Effects of a brief multimedia psychoeducational intervention on the attitudes and interest of patients with cancer regarding clinical trial participation: a multicenter randomized controlled trial. J Clin Oncol. 2012 Jul;30(20):2516-2521. Pubmedid: 22614993.
  • Nishihori T, Alekshun TJ, Shain K, Sullivan DM, Baz R, Perez L, Pidala J, Kharfan-Dabaja MA, Ochoa-Bayona JL, Fernandez HF, Yarde DN, Oliveira V, Fulp W, Han G, Kim J, Chen DT, Raychaudhuri J, Dalton W, Anasetti C, Alsina M. Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma. Brit J Haematol. 2012 Jun;157(5):553-563. Pubmedid: 22449149. Pmcid: PMC4030553.
  • Strosberg JR, Yeatman T, Weber J, Coppola D, Schell MJ, Han G, Almhanna K, Kim R, Valone T, Jump H, Sullivan D. A phase II study of RO4929097 in metastatic colorectal cancer. Eur J Cancer. 2012 May;48(7):997-1003. Pubmedid: 22445247.
  • Turner JG, Dawson J, Sullivan DM. Nuclear export of proteins and drug resistance in cancer. Biochem Pharmacol. 2012 Apr;83(8):1021-1032. Pubmedid: 22209898.
  • Chen F, Pisklakova A, Li M, Baz R, Sullivan DM, Nefedova Y. Gamma-secretase inhibitor enhances the cytotoxic effect of bortezomib in multiple myeloma. Cell Oncol (Dordr). 2011 Dec;34(6):545-551. Pubmedid: 21965140. Pmcid: PMC3417352.
  • Garrett CR, Coppola D, Wenham RM, Cubitt CL, Neuger AM, Frost TJ, Lush RM, Sullivan DM, Cheng JQ, Sebti SM. Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT. Invest New Drugs. 2011 Dec;29(6):1381-1389. Pubmedid: 20644979.
  • Lebovic D, Zhang L, Alsina M, Nishihori T, Shain KH, Sullivan D, Ochoa-Bayona JL, Kharfan-Dabaja MA, Baz R. Clinical outcomes of patients with plasma cell leukemia in the era of novel therapies and hematopoietic stem cell transplantation strategies: a single-institution experience. Clin Lymphoma Myeloma Leuk. 2011 Dec;11(6):507-511. Pubmedid: 21813352.
  • Yap TA, Yan L, Patnaik A, Fearen I, Olmos D, Papadopoulos K, Baird RD, Delgado L, Taylor A, Lupinacci L, Riisnaes R, Pope LL, Heaton SP, Thomas G, Garrett MD, Sullivan DM, de Bono JS, Tolcher AW. First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors. J Clin Oncol. 2011 Dec;29(35):4688-4695. Pubmedid: 22025163.
  • Perkins JB, Goldstein SC, Dawson JL, Kim J, Field TL, Partyka JS, Fields KK, Maddox BL, Simonelli CE, Neuger AM, Lush RM, Sullivan DM. Phase I Study of Topotecan, Ifosfamide, and Etoposide (TIME) with autologous stem cell transplant in refractory cancer: pharmacokinetic and pharmacodynamic correlates. Clin Cancer Res. 2011 Dec;17(24):7743-7753. Pubmedid: 22028494.
  • O'Neil BH, Goff LW, Kauh JS, Strosberg JR, Bekaii-Saab TS, Lee RM, Kazi A, Moore DT, Learoyd M, Lush RM, Sebti SM, Sullivan DM. Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2011 Aug;29(17):2350-2356. Pubmedid: 21519015. Pmcid: PMC3107750.
  • Lancet JE, Duong VH, Winton EF, Stuart RK, Burton M, Zhang S, Cubitt C, Blaskovich MA, Wright JJ, Sebti S, Sullivan DM. A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias. Clin Cancer Res. 2011 Mar;17(5):1140-1146. Pubmedid: 21233404. Pmcid: PMC3049960.
  • Reece DE, Sullivan D, Lonial S, Mohrbacher AF, Chatta G, Shustik C, Burris H, Venkatakrishnan K, Neuwirth R, Riordan WJ, Karol M, von Moltke LL, Acharya M, Zannikos P, Keith Stewart A. Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma. Cancer Chemother Pharmacol. 2011 Jan;67(1):57-67. Pubmedid: 20306195.
  • Dalton WS, Sullivan DM, Yeatman TJ, Fenstermacher DA. The 2010 Health Care Reform Act: a potential opportunity to advance cancer research by taking cancer personally. Clin Cancer Res. 2010 Dec;16(24):5987-5996. Pubmedid: 21169252.
  • Li M, Chen F, Clifton N, Sullivan DM, Dalton WS, Gabrilovich DI, Nefedova Y. Combined inhibition of Notch signaling and Bcl-2/Bcl-xL results in synergistic antimyeloma effect. Mol Cancer Ther. 2010 Dec;9(12):3200-3209. Pubmedid: 21159606. Pmcid: PMC3058809.
  • Perkins J, Field T, Kim J, Kharfan-Dabaja MA, Fernandez H, Ayala E, Perez L, Xu M, Alsina M, Ochoa L, Sullivan D, Janssen W, Anasetti C. A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxis. Biol Blood Marrow Tran. 2010 Jul;16(7):937-947. Pubmedid: 20102746.
  • Hartley-Brown MA, Sullivan DM, Baz R. State-of-the-Art Management of Complications of Myeloma and Its Treatment. Adv Hematol. 2010 Jun;2010:343089. Pubmedid: 20671999.
  • Moffitt K, Brogan F, Brown C, Kasper M, Rosenblatt J, Smallridge R, Sullivan D, Kromrey J. Statewide cancer clinical trial navigation service. J Oncol Pract. 2010 May;6(3):127-132. Pubmedid: 20808555.
  • Field T, Perkins J, Huang Y, Kharfan-Dabaja MA, Alsina M, Ayala E, Fernandez HF, Janssen W, Lancet J, Perez L, Sullivan D, List A, Anasetti C. 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2010 Feb;45(2):255-260. Pubmedid: 19543327.
  • Turner JG, Marchion DC, Dawson JL, Emmons MF, Hazlehurst LA, Washausen P, Sullivan DM. Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition. Cancer Res. 2009 Sep;69(17):6899-6905. Pubmedid: 19690141. Pmcid: PMC2744372.
  • Homsi J, Cubitt CL, Zhang S, Munster PN, Yu H, Sullivan DM, Jove R, Messina JL, Daud AI. Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma. Melanoma Res. 2009 Jun;19(3):167-175. Pubmedid: 19434004.
  • Daud AI, Dawson J, Deconti RC, Bicaku E, Marchion D, Bastien S, Hausheer FA, Lush R, Neuger A, Sullivan DM, Munster PN. Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial. Clin Cancer Res. 2009 Apr;15(7):2479-2487. Pubmedid: 19318485.
  • Munster P, Marchion D, Bicaku E, Lacevic M, Kim J, Centeno B, Daud A, Neuger A, Minton S, Sullivan D. Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC. Clin Cancer Res. 2009 Apr;15(7):2488-2496. Pubmedid: 19318486.
  • Daud AI, DeConti RC, Andrews S, Urbas P, Riker AI, Sondak VK, Munster PN, Sullivan DM, Ugen KE, Messina JL, Heller R. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol. 2008 Dec;26(36):5896-5903. Pubmedid: 19029422. Pmcid: PMC2645111.
  • Moulder S, Valkov N, Neuger A, Choi J, Lee JH, Minton S, Munster P, Gump J, Lacevic M, Lush R, Sullivan D. Phase 2 study of gemcitabine and irinotecan in metastatic breast cancer with correlatives to determine topoisomerase I localization as a predictor of response. Cancer. 2008 Nov;113(10):2646-2654. Pubmedid: 18823053.
  • Yeatman TJ, Mule J, Dalton WS, Sullivan D. On the eve of personalized medicine in oncology. Cancer Res. 2008 Sep;68(18):7250-7252. Pubmedid: 18794109.
  • Cangiano J, Centeno BA, Garrett CR, Caceres W, de Jesus A, Lee JH, Pavia O, Jove R, Baez L, Sullivan DM, Muro-Cacho CA, Munoz-Antonia T. Signal transduction proteins in tumors from Puerto Rican and Caucasian gastric adenocarcinoma patients: expression differences with potential for specific targeted therapies. Dig Dis Sci. 2008 Aug;53(8):2090-2100. Pubmedid: 18224443.
  • Chiappori AA, Haura E, Rodriguez FA, Boulware D, Kapoor R, Neuger AM, Lush R, Padilla B, Burton M, Williams C, Simon G, Antonia S, Sullivan DM, Bepler G. Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer. Clin Cancer Res. 2008 Mar;14(5):1464-1469. Pubmedid: 18316570.
  • Nefedova Y, Sullivan D, Bolick S, Dalton W, Gabrilovich D. Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy. Blood. 2008 Feb;111(4):2220-2229. Pubmedid: 18039953.
  • Turner J, Sullivan D. CRM1-mediated nuclear export of proteins and drug resistance in cancer. Curr Med Chem. 2008;15(26):2648-2655. Pubmedid: 18991627.
  • Homsi J, Simon G, Garrett C, Springett G, DeConti R, Chiappori A, Munster PN, Burton M, Stromatt S, Allievi C, Angiuli P, Eisenfeld A, Sullivan D, Daud A. Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies. Clin Cancer Res. 2007 Oct;13(19):5855-5861. Pubmedid: 17908979.
  • Münster P, Marchion D, Bicaku E, Schmitt M, Lee JH, DeConti R, Simon G, Fishman M, Minton S, Garrett C, Chiappori A, Lush R, Sullivan D, Daud A. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J Clin Oncol. 2007 May;25(15):1979-1985. Pubmedid: 17513804.
  • de Lima Lopes G, Chiappori A, Simon G, Haura E, Sullivan D, Antonia S, Langevin M, Lush R, Rocha-Lima CM. Phase I study of carboplatin in combination with gemcitabine and irinotecan in patients with solid tumors: preliminary evidence of activity in small cell and neuroendocrine carcinomas. Cancer. 2007 Apr;109(7):1413-1419. Pubmedid: 17326096.
  • Chiappori AA, Eckhardt SG, Bukowski R, Sullivan DM, Ikeda M, Yano Y, Yamada-Sawada T, Kambayashi Y, Tanaka K, Javle MM, Mekhail T, O'bryant CL, Creaven PJ. A phase I pharmacokinetic and pharmacodynamic study of s-3304, a novel matrix metalloproteinase inhibitor, in patients with advanced and refractory solid tumors. Clin Cancer Res. 2007 Apr;13(7):2091-2099. Pubmedid: 17404091.
  • Kelloff GJ, Sullivan DM, Wilson W, Cheson B, Juweid M, Mills GQ, Zelenetz AD, Horning SJ, Weber W, Sargent DJ, Dodd L, Korn E, Armitage J, Schilsky R, Christian M, O'connor OA, Wang SJ, Farrell AT, Pazdur R, Graham M, Wahl RL, Larson SM, Kostakoglu L, Daube-Witherspoon M, Gastonis C, Siegel BA, Shankar LK, Lee DB, Higley HR, Sigman CC, Carucci D, Timko D, deGennaro LJ, Sigal E, Barker A, Woodcock J. FDG-PET lymphoma demonstration project invitational workshop. Acad Radiol. 2007 Mar;14(3):330-339. Pubmedid: 17307666.
  • Fracasso PM, Burris H, Arquette MA, Govindan R, Gao F, Wright LP, Goodner SA, Greco FA, Jones SF, Willcut N, Chodkiewicz C, Pathak A, Springett GM, Simon GR, Sullivan DM, Marcelpoil R, Mayfield SD, Mauro D, Garrett CR. A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosing. Clin Cancer Res. 2007 Feb;13(3):986-993. Pubmedid: 17289894.
  • Turner JG, Gump JL, Zhang C, Cook JM, Marchion D, Hazlehurst L, Munster P, Schell MJ, Dalton WS, Sullivan DM. ABCG2 expression, function, and promoter methylation in human multiple myeloma. Blood. 2006 Dec;108(12):3881-3889. Pubmedid: 16917002. Pmcid: PMC1895461.
  • Allina J, Hu B, Sullivan DM, Fiel MI, Thung SN, Bronk SF, Huebert RC, van de Water J, LaRusso NF, Gershwin ME, Gores GJ, Odin JA. T cell targeting and phagocytosis of apoptotic biliary epithelial cells in primary biliary cirrhosis. J Autoimmun. 2006 Dec;27(4):232-241. Pubmedid: 17222534.
  • Simon G, Lush R, Gump J, Tetteh L, Williams C, Cantor A, Antonia S, Garrett C, Rocha-Lima C, Fishman M, Sullivan D, Munster P. Sequential oral 9-nitrocamptothecin and etoposide: a pharmacodynamic- and pharmacokinetic-based phase I trial. Mol Cancer Ther. 2006 Aug;5(8):2130-2137. Pubmedid: 16928835.
  • Simon GR, Garrett CR, Olson SC, Langevin M, Eiseman IA, Mahany JJ, Williams CC, Lush R, Daud A, Munster P, Chiappori A, Fishman M, Bepler G, Lenehan PF, Sullivan DM. Increased bioavailability of intravenous versus oral CI-1033, a pan erbB tyrosine kinase inhibitor: results of a phase I pharmacokinetic study. Clin Cancer Res. 2006 Aug;12(15):4645-4651. Pubmedid: 16899614.
  • Emmons M, Boulware D, Sullivan DM, Hazlehurst LA. Topoisomerase II beta levels are a determinant of melphalan-induced DNA crosslinks and sensitivity to cell death. Biochem Pharmacol. 2006 Jun;72(1):11-18. Pubmedid: 16678798.
  • Shankar LK, Hoffman JM, Bacharach S, Graham MM, Karp J, Lammertsma AA, Larson S, Mankoff DA, Siegel BA, Van den Abbeele A, Yap J, Sullivan D. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med. 2006 Jun;47(6):1059-1066. Pubmedid: 16741317.
  • Nakanishi T, Bailey-Dell KJ, Hassel BA, Shiozawa K, Sullivan DM, Turner J, Ross DD. Novel 5' untranslated region variants of BCRP mRNA are differentially expressed in drug-selected cancer cells and in normal human tissues: implications for drug resistance, tissue-specific expression, and alternative promoter usage. Cancer Res. 2006 May;66(10):5007-5011. Pubmedid: 16707421.
  • Sharp JS, Sullivan DM, Cavanagh J, Tomer KB. Measurement of multisite oxidation kinetics reveals an active site conformational change in Spo0F as a result of protein oxidation. Biochemistry-Us. 2006 May;45(20):6260-6266. Pubmedid: 16700537.
  • Hazlehurst L, Argilagos R, Emmons M, Boulware D, Beam C, Sullivan D, Dalton W. Cell adhesion to fibronectin (CAM-DR) influences acquired mitoxantrone resistance in U937 cells. Cancer Res. 2006 Feb;66(4):2338-2345. Pubmedid: 16489039.
  • Gritsko T, Williams A, Turkson J, Kaneko S, Bowman T, Huang M, Nam S, Eweis I, Diaz N, Sullivan D, Yoder S, Enkemann S, Eschrich S, Lee JH, Beam CA, Cheng J, Minton S, Muro-Cacho CA, Jove R. Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res. 2006 Jan;12(1):11-19. Pubmedid: 16397018.
  • Fishman M, Garrett C, Simon G, Chiappori A, Lush R, Dinwoodie W, Mahany J, Dellaportas A, Cantor A, Gollerki A, Cohen M, Sullivan D. Phase I study of the taxane BMS-188797 in combination with carboplatin administered every 3 weeks in patients with solid malignancies. Clin Cancer Res. 2006 Jan;12(2):523-528. Pubmedid: 16428495.
  • Diaz N, Minton S, Cox C, Bowman T, Gritsko T, Garcia R, Eweis I, Wloch M, Livingston S, Seijo E, Cantor A, Lee JH, Beam CA, Sullivan D, Jove R, Muro-Cacho CA. Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression. Clin Cancer Res. 2006 Jan;12(1):20-28. Pubmedid: 16397019.
  • Marchion DC, Bicaku E, Turner JG, Daud AI, Sullivan DM, Munster PN. Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta. Clin Cancer Res. 2005 Dec;11(23):8467-8475. Pubmedid: 16322310.
  • Marchion DC, Bicaku E, Daud AI, Sullivan DM, Munster PN. In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates. Mol Cancer Ther. 2005 Dec;4(12):1993-2000. Pubmedid: 16373714.
  • Lush RM, McCune J, Tetteh L, Thompson JA, Mahany JH, Garland L, Suttle AB, Sullivan DM. The absolute bioavailability of oral vinorelbine in patients with solid tumors. Cancer Chemother Pharmacol. 2005 Dec;56(6):578-584. Pubmedid: 16001165.
  • Marchion D, Bicaku E, Daud A, Sullivan D, Munster P. Valproic acid alters chromatin structure by regulation of chromatin modulation proteins. Cancer Res. 2005 May;65(9):3815-3822. Pubmedid: 15867379.
  • Garrett CR, Fishman MN, Rago RR, Williams CC, Dellaportas AM, Mahany JJ, Lush RM, Dalton WS, Gollerkeri A, Cohen MB, Sullivan DM. Phase I study of a novel taxane BMS-188797 in adult patients with solid malignancies. Clin Cancer Res. 2005 May;11(9):3335-3341. Pubmedid: 15867232.
  • Gillies RJ, Hoffman JM, Lam KS, Menkens AE, Piwnica-Worms DR, Sullivan DC, Weissleder R. Meeting report: high-throughput technologies for in vivo imaging agents. Mol Imaging. 2005 Apr;4(2):98-103. Pubmedid: 16105507.
  • Daud A, Valkov N, Centeno B, Derderian J, Sullivan P, Munster P, Urbas P, Deconti R, Berghorn E, Liu Z, Hausheer F, Sullivan D. Phase II trial of karenitecin in patients with malignant melanoma: clinical and translational study. Clin Cancer Res. 2005 Apr;11(8):3009-3016. Pubmedid: 15837755.
  • Yen Y, Margolin K, Doroshow J, Fishman M, Johnson B, Clairmont C, Sullivan D, Sznol M. A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer. Cancer Chemother Pharmacol. 2004 Oct;54(4):331-342. Pubmedid: 15148626.
  • Sood A, Lush R, Geisler J, Shahin M, Sanders L, Sullivan D, Buller R, Sorosky J. Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: results of a phase II trial. Clin Cancer Res. 2004 Sep;10(18 Pt 1):6080-6085. Pubmedid: 15447993.
  • Turner JG, Engel R, Derderian JA, Jove R, Sullivan DM. Human topoisomerase IIalpha nuclear export is mediated by two CRM-1-dependent nuclear export signals. J Cell Sci. 2004 Jun;117(Pt 14):3061-3071. Pubmedid: 15173319.
  • Alsina M, Fonseca R, Wilson EF, Belle AN, Gerbino E, Price-Troska T, Overton RM, Ahmann G, Bruzek LM, Adjei AA, Kaufmann SH, Wright JJ, Sullivan D, Djulbegovic B, Cantor AB, Greipp PR, Dalton WS, Sebti SM. Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood. 2004 May;103(9):3271-3277. Pubmedid: 14726402.
  • Engel R, Valkov N, Gump J, Hazlehurst L, Dalton W, Sullivan D. The cytoplasmic trafficking of DNA topoisomerase IIalpha correlates with etoposide resistance in human myeloma cells. Exp Cell Res. 2004 May;295(2):421-431. Pubmedid: 15093741.
  • Marchion DC, Bicaku E, Daud AI, Richon V, Sullivan DM, Munster PN. Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid. J Cell Biochem. 2004 May;92(2):223-237. Pubmedid: 15108350.
  • Moulder S, Mahany J, Lush R, Rocha-Lima C, Langevin M, Ferrante K, Bartkowski L, Kajiji S, Noe D, Paillet S, Sullivan D. A phase I open label study of the farnesyltransferase inhibitor CP-609,754 in patients with advanced malignant tumors. Clin Cancer Res. 2004;10(21):7127-7135. Pubmedid: 15534083.
  • Valkov NI, Sullivan DM. Tumor p53 status and response to topoisomerase II inhibitors. Drug Resist Updat. 2003 Feb;6(1):27-39. Pubmedid: 12654285.
  • Hazelhurst LA, Valkov N, Wisner L, Storey JA, Boulware D, Sullivan DM, Dalton WS. Reduction in drug-induced DNA double-strand breaks associated with beta1 integrin-mediated adhesion correlates with drug resistance in U937 cells. Blood. 2001 Sep;98(6):1897-1903. Pubmedid: 11535527.
  • Haldane A, Sullivan D. DNA topoisomerase II-catalyzed DNA decatenation. Methods Mol Biol. 2001;95:13-23. Pubmedid: 11089215.
  • Tsai S, Valkov N, Yang W, Gump J, Sullivan D, Seto E. Histone deacetylase interacts directly with DNA topoisomerase II. Nat Genet. 2000;26(3):349-353. Pubmedid: 11062478.
  • Valkov N, Kirsch I, Gump J, Engel R, Sullivan D. Cell density-dependent VP-16 sensitivity of leukaemic cells is accompanied by the translocation of topoisomerase IIalpha from the nucleus to the cytoplasm. Br J Haematol. 2000;108(2):331-345. Pubmedid: 10691864.
  • Hochhauser D, Valkov N, Gump J, Wei I, Fu J, Ohare C, Hartley J, Bertino J, Banerjee D, Sullivan D. Effects of wild-type p53 expression on the quality and activity of topoisomerase IIalpha and beta in various human cancer cell lines. J Cell Biochem. 1999;75(2):245-257. Pubmedid: 10502297.
  • Weitzner M, Lehninger F, Sullivan D, Fields K. Borderline personality disorder and bone marrow transplantation: ethical considerations and review. Psychol Oncol. 1999;8(1):46-54. Pubmedid: 10202782.
  • Dong Q, Johnson S, Colvin O, Bullock N, Kilborn C, Runyon G, Sullivan D, Eaton J, Bigner J, Modrich P. Multiple DNA repair mechanisms and alkylator resistance in the human medulloblastoma cell line D-283 Med (4-HCR). Cancer Chemother Pharmacol. 1999;43(1):73-79. Pubmedid: 9923544.
  • Turnbull R, Meczes E, Rogers M, Lock R, Sullivan D, Finlay G, Baguley B, Austin C. Carbamate analogues of amsacrine active against non-cycling cells: relative activity against topoisomerases IIalpha and beta. Cancer Chemother Pharmacol. 1999;44:275-282. Pubmedid: 10447574.
  • Sullivan D, Partyka J, Fields K, Goldstein S, Field T, Djulbegovic B, Perkins J, McIssac C, Lush, III R, Dalton W. A Phase I study of intensive-dose melphalan, topotecan and VP-16 phosphate (MTV) followed by autologous stem cell rescue in patients with multiple myeloma. Clin Cancer Res. 1999;5:3734s-3734s. Pubmedid: noPMID.
  • Turner JG, Tan J, Crucian BE, Sullivan DM, Ballester OF, Dalton WS, Yang NS, Burkholder JK, Yu H. Broadened clinical utility of gene gun-mediated, granulocyte-macrophage colony-stimulating factor cDNA-based tumor cell vaccines as demonstrated with a mouse myeloma model. Hum Gene Ther. 1998 May;9(8):1121-1130. Pubmedid: 9625251.
  • Fields K, Elfenbein G, Perkins J, Ballester O, Goldstein S, Heimenz J, Saez R, Sullivan D, Partyka J, Kronish L. Defining the role of novel high-dose chemotherapy regimens for the treatment of high-risk breast cancer. Semin Oncol. 1998 Apr;25(2 Suppl 4):1-6. Pubmedid: 9578055.
  • Djulbegovic B, Hozo I, Fields K, Sullivan D. High-dose chemotherapy in the adjuvant treatment of breast cancer: benefit risk analysis. Cancer Control. 1998;5:394-405. Pubmedid: 10761089.
  • Valkov N, Gump J, Sullivan D. Quantitative immunofluorescence and immunoelectron microscopy of the topoisomerase II-alpha associated with nuclear matrices from wild-type and drug resistant Chinese hamster ovary cell lines. J Cell Biochem. 1997 Oct;67(1):112-130. Pubmedid: 9328845.
  • Ballester OF, Tummala R, Janssen WE, Fields KK, Hiemenz JW, Goldstein SC, Perkins JB, Sullivan DM, Rosen R, Sackstein R, Zorsky P, Saez R, Elfenbein GJ. High-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma and renal insufficiency. Bone Marrow Transplant. 1997 Oct;20(8):653-656. Pubmedid: 9383228.
  • Lock R, Thompson B, Sullivan D, Stribinskiene L. Potentiation of etoposide-induced apoptosis by staurosporine in human tumor cells is associated with events downstream of DNA-protein complex formation. Cancer Chemother Pharmacol. 1997;39(5):399-409. Pubmedid: 9054953.
  • Futscher B, Foley N, Gleason-Guzman M, Meltzer P, Sullivan D, Dalton W. Verapamil suppresses the emergence of P-glycoprotein-mediated multi-drug resistance. Int J Cancer. 1996 May;66(4):520-525. Pubmedid: 8635868.
  • Harker W, Slade D, Parr R, Feldhoff P, Sullivan D, Holguin M. Alterations in the Topoisomerase II-alpha gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II-beta enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line. Cancer Res. 1995 Apr;55(8):1707-1716. Pubmedid: 7712479.
  • Sullivan D, Feldhoff P, Lock R, Smith N, Pierce W. Characterization of an altered DNA topoisomerase II-alpha from a mitoxantrone resistant mammalian cell line hypersensitive to DNA crosslinking agents. Int J Oncology. 1995;7:1383-1393. Pubmedid: noPMID.
  • Burden D, Sullivan D. Phosphorylation of the (alpha) and (beta) isoforms of DNA topoisomerase II is qualitatively different in interphase and mitosis in Chinese hamster ovary cells. Biochemistry. 1994 Dec;33(49):14651-14655. Pubmedid: 7993892.
  • Feldhoff P, Mirski S, Cole S, Sullivan D. Altered subcellular distribution of topoisomerase II (alpha) in a drug-resistant human small cell lung cancer cell line. Cancer Res. 1994 Feb;54(3):756-762. Pubmedid: 8306338.
  • Burden D, Goldsmith L, Sullivan D. Cell cycle-dependent phosphorylation and activity of Chinese hamster ovary topoisomerase II. Biochem J. 1993 Jul;293(Pt 1):297-304. Pubmedid: 8392338.
  • Blumenrich M, Kellihan J, Joseph U, Lalley K, Sherrill E, Sullivan D, Hamm J, Gentile P, Sheth S, Seeger J, Woodcock T. Long-term intravenous hydroxyurea infusion in patients with advanced cancer. Cancer. 1993 May;71(9):2828-2832. Pubmedid: 7682153.
  • Kroll D, Sullivan D, Gutierrez-Hartmann, Hoeffler J. Modification of DNA topoisomerase II activity via direct interactions with the cyclic adenosine-3',5'-monophosphate response element-binding protein and related transcription factors. Mol Endocrinol. 1993 Mar;7(3):305-318. Pubmedid: 8387155.
  • Sullivan DM, Eskildsen LA, Groom KR, Webb CD, Latham MD, Martin AW, Wellhausen SR, Kroeger PE, Rowe TC. Topoisomerase II activity involved in cleaving DNA into topological domains is altered in a multiple drug-resistant Chinese hamster ovary cell line. Mol Pharmacol. 1993 Feb;43(2):207-216. Pubmedid: 8094226.
  • Stoddard M, Seeger J, Liddell N, Hadley T, Sullivan D, Kupersmith J. J Am Coll Cardiol. 1992;20:62-69. Pubmedid: 1607540.
  • Fields K, Perkins J, Elfenbein G, Goldstein S, Sullivan D, Pertyka J, Trudeau W. Evaluation of prognostic factors for patients with breast cancer undergoing high-dose chemotherapy and autologous stem cell transplant: a single institution experience. In: Dicke K, Keating A, eds. Autologous blood and marrow transplantation, proceedings of the 9th international symposium. Charlottesville, VA: Carden Jennings; 1999;341-352.
  • Fields K, Goldstein S, Clark R, Sullivan D. Breast Cancer. In: Djulbegovic B, Sullivan D, eds. Decision Making in Oncology: Evidence Based Management. New York, NY: Churchill Livingstone Inc.; 1997;253-265.
  • Fields K, Perkins J, Goldstein S, Elfenbein G, Saez R, Sullivan D, Partyka J, Kronish L. High dose chemotherapy for the treatment of high risk, early stage breast cancer: analysis of risk factors. In: Untech M, Konecny G, Sittek H, Kessler M, et al, eds. Diagnostik and Therapie Des Mammakarzinoms. Verlag, Munchen. W. Zuckeschwerdt; 1998.
  • Holkova B, Perkins EB, Ramakrishnan V, Tombes MB, Shrader E, Talreja N, Wellons MD, Hogan KT, Roodman GD, Coppola D, Kang L, Dawson J, Stuart RK, Peer C, Figg WD, Kolla S, Doyle A, Wright J, Sullivan DM, Roberts JD, Grant S. Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms. Clin Cancer Res. 2011 May;17(10):3388-3397. Pubmedid: 21447728. Pmcid: PMC3096752.
  • Fishman M, Sullivan D. Application of resistance reversal agents in hematologic malignancies; malignancy; current clinical practice. Hematology. 2000;5(5):343-358. Pubmedid: 11399634.
  • Holkova B, Kmieciak M, Perkins EB, Bose P, Baz R, Roodman GD, Stuart RK, Ramakrishnan V, Wan W, Peer CJ, Dawson JL, Kang L, Honeycutt C, Tombes MB, Shrader E, Weir-Wiggins C, Wellons M, Sankala HM, Hogan K, Colevas AD, Doyle A, Figg WD, Coppola D, Roberts JD, Sullivan DM, Grant S. Phase I Trial of Bortezomib (PS-341; NSC 681239) and "Nonhybrid" (Bolus) Infusion Schedule of Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-cell Neoplasms. Clin Cancer Res. 2014 Nov;20(22):5652-5662. Pubmedid: 25248382.
  • Bhalla K, Gerson S, Grant S, Sullivan D. Pharmacology and molecular mechanism of action or resistance of antineoplastic agents: current status and future potential. In: Hoffman R, Benz E, Shattil S, Furie B, et al, eds. Hematology: basic principles and practice. New York, NY: Chuchhill Livingston; 2000;885-938.
TOOLS:   Font Size small font resizer separator font resizer separator big font resizer
 |  Site Map  |  Privacy Policy  |  Terms and Conditions